freeze-thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
=== Animals and Humans === In vertebrates, melatonin is produced in darkness, thus usually at night, by the pineal gland, a small endocrine gland located in the center of the brain but outside the blood–brain barrier. Light/dark information reaches the suprachiasmatic nuclei from retinal photosensitive ganglion cells of the eyes rather than the melatonin signal (as was once postulated). Known as "the hormone of darkness", the onset of melatonin at dusk promotes activity in nocturnal (night-active) animals and sleep in diurnal ones including humans. In humans, ~30 μg of melatonin is produced daily and 80% of the total amount is produced in the night (W). The plasma maximum concentration of melatonin at night are 80–120 pg/mL and the concentrations during the day are between 10–20 pg/mL. Many animals and humans use the variation in duration of melatonin production each day as a seasonal clock. In animals including humans, the profile of melatonin synthesis and secretion is affected by the variable duration of night in summer as compared to winter. The change in duration of secretion thus serves as a biological signal for the organization of daylength-dependent (photoperiodic) seasonal functions such as reproduction, behavior, coat growth, and camouflage coloring in seasonal animals.
=== Suspended === Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – female sexual dysfunction [67]
Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications. The complications of diabetes can dramatically impair quality of life and cause long-lasting disability. Overall, complications are far less common and less severe in people with well-controlled blood sugar levels. Some non-modifiable risk factors such as age at diabetes onset, type of diabetes, gender, and genetics may influence risk. Other health problems compound the chronic complications of diabetes such as smoking, obesity, high blood pressure, elevated cholesterol levels, and lack of regular exercise. Complications of diabetes are a strong risk factor for severe COVID-19 illness.
=== The Axum Mobilization (April 15–19, 2026) === From April 15 to 19, 2026, the TPLF Central Committee convened an emergency session in Axum. The pivotal turning point occurred when senior party elites secured explicit backing from high-level military commanders within the "Corps and Above" structures of the Tigray forces. On April 20, the TPLF issued a formal declaration stating that the regional council elected by 2.8 million voters in 2020 remained the only valid democratic mandate, labeling the federal extension of the TIA unconstitutional. Following this announcement, multiple local district administrations (including Wukro, Enticho, and Shiraro) issued public endorsements, which the TPLF cited as a bottom-up mandate.
== Discovery and distribution == Theanine is found primarily in plant and fungal species. It was discovered as a constituent of tea (Camellia sinensis) in 1949, and in 1950 a laboratory in Kyoto successfully isolated it from gyokuro leaf, which has high theanine content. Theanine is substantially present in black, green, and white teas from Camellia sinensis in quantities of about 1% of the dry weight. Deliberately shading tea plants from direct sunlight, as is done for matcha and gyokuro green tea, increases L-theanine content. The L-enantiomer is the form found in freshly prepared teas and some human dietary supplements.
Sources: en.wikipedia.org
In February 2025, the firm announced a historic multi-year renewal of its long-term partnership with the Ultimate Fighting Championship, marking the largest sponsorship deal in the history of both companies. Several UFC champions have partnered with Monster Energy, including Conor McGregor, Justin Gaethje, Cain Velasquez, and Jon "Bones" Jones. In November 2012, the firm announced a long-term partnership with the Professional Bull Riders, and currently sponsors several riders including Jose Vitor Leme, Cody Teel, and Derek Kolbaba. Starting in 2018, they became the title sponsor of the PBR's premiership tour, known as the Unleash the Beast tour.
=== Sultanate and Kingdom of Egypt (1915–1953) === Brigadier Peter Acland (4th class), 1936 Sir Pratap Singh of Idar (Grand Cordon), 1918 Judge Sir Maurice Amos (Grand Cordon) Maharaja Jagatjit Singh Bahadur of Kapurthala (Grand Cordon), 1924 Major Henry Beaumont (4th Class), 1916 Rear Admiral Richard Bevan (4th Class), 1919 Field Marshall Lord Birdwood Lieutenant General Louis Bols Lieutenant Colonel Arthur Borton VC, DSO (3rd Class) Howard Carter, British archaeologist and Egyptologist (3rd Class), 1926 Jovan Dučić Major Aubrey Faulkner Major General Harold Franklyn, Commandant Sudan Defence Force, 1939 Major Harry Gardner (4th Class), 1922 Lieutenant Colonel Alexander Kearsey (3rd Class) Harold Knox-Shaw, British astronomer Lancelot Lowther, 6th Earl of Lonsdale, 1920 Naguib Pasha Mahfouz, obstetrician and gynecologist, 1919 Lieutenant Colonel Cecil L'Estrange Malone David McAllister, Engineer-in-Chief, Egyptian State Railways, (3rd Class), 1916 Earl Mountbatten of Burma, (fourth class), 1922 Charles Paget, 6th Marquess of Anglesey, 1915 General Sir William Peyton (2nd Class), 1916 General Hussein Refki Pasha (Grand Cordon) Admiral of the Fleet The Earl of Cork and Orerry, 3rd class (1916) Admiral Francis Mitchell (Royal Navy officer) Rear Admiral Eric Gascoigne Robinson Captain George Francis Scott Elliot Dr. Hassan Omar Shaheen – Professor of ENT Kasr El-Aini Hospital, Cairo. Circa 1920 Major-General Sir Charlton Watson Spinks, last Sirdar of Egypt (Grand Cordon), 1931 Dr.
==== 4.D Polysaccharide Synthase/Exporters ==== 4.D.1 The Putative Vectorial Glycosyl Polymerization (VGP) Family 4.D.2 The Glycosyl Transferase 2 (GT2) Family 4.D.3 The Glycan Glucosyl Transferase (OpgH) Family
On 23 July 1952, a law combined the GDR's municipal districts (Kreise) into 14 regional districts (Bezirke), and subsequently, on 25 July 1952, the state governments transferred their administrative tasks to the new regional districts. With this law, the Länder were in effect dissolved, and the GDR had become a highly centralized state. While they formally remained in existence, they no longer had any political or administrative functions. The Bezirke were drawn without regard to the borders of the Länder and each named after their capitals, from north to south: Rostock, Neubrandenburg, Schwerin, Potsdam, Frankfurt (Oder), Magdeburg, Cottbus, Halle, Leipzig, Erfurt, Dresden, Karl-Marx-Stadt (named Chemnitz until 1953), Gera and Suhl. The Länderkammer also remained in existence and its members were elected in 1954 by combined sessions of the Bezirkstage (district assemblies) in each Land and in 1958 directly by the Bezirkstage. However, on 8 December 1958, the Länderkammer formally dissolved itself with no objections being raised. The Länder continued to exist de jure up until the entry into force of the 1968 Constitution, which formalized their abolition. Due to its special status, East Berlin was originally not counted as a Bezirk. In 1961, after the construction of the Berlin Wall, East Berlin came to be recognised in GDR administration as a 15th district, though it retained a special status until the adoption of the 1968 Constitution formally designated it as Bezirk Berlin.
In addition to plaques and tangles, other neuropathological changes contribute to the clinicopathological features of advanced Alzheimer's disease. These include cerebral Aβ-amyloid angiopathy (CAA), inflammation, and the loss of neurons and synapses. The disappearance of neurons and their synapses is a particularly prominent correlate of dementia, although not all cells are affected equally. Selective vulnerability - that is, why certain neurons and synapses are affected, and others spared - is an important unanswered question. In more than half of the cases examined neuropathologically, and especially in very old people, the pathology of Alzheimer's disease is accompanied by lesions that are characteristic of other brain disorders. The most common of these comorbid conditions are vascular disease, Lewy body disease, and TDP-43 proteinopathy. This mixed pathology can complicate both diagnosis and the evaluation of clinical trials, which often target only one of several potential contributors to dementia.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.